CHICAGO (EGMN) - Long-term follow-up confirms that continuous infusion of doxorubicin offers no cardioprotective advantage over bolus infusion in children treated for acute lymphoblastic leukemia.Echocardiograms performed at a median of 8 years post randomization revealed no significant differences in cardiac parameters between the infusion and bolus groups, although both groups showed significant progressive abnormalities of left ventricular (LV) structure and function, said Dr. Steven Lipshultz,...